{"gene":"CXCR1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2001,"finding":"IL-8 activation of CXCR1 on microvascular endothelial cells induces early-phase actin stress fiber formation via a Rho/Rho-kinase signaling cascade (blocked by C3 botulinum toxin and Y-27632, but not pertussis toxin), distinct from CXCR2-mediated later-phase cell retraction via Gi and Rac.","method":"Dominant-negative Rho and Rac overexpression, C3 botulinum toxin, pertussis toxin treatment, CXCR1/CXCR2-specific blocking antibodies in microvascular endothelial cells","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 1/2 / Moderate — multiple pharmacological and genetic tools (dominant negatives, bacterial toxins, blocking antibodies) in a single study with clear mechanistic resolution of CXCR1 vs CXCR2 signaling arms","pmids":["11350788"],"is_preprint":false},{"year":1999,"finding":"Agonist-induced CXCR1 internalization requires GRK2, beta-arrestins, and dynamin, and proceeds via clathrin-coated vesicles; dominant-negative beta-arrestin 1-V53D and dynamin I-K44A both block CXCR1-GFP internalization.","method":"CXCR1-GFP fusion protein expression in HEK293 and RBL-2H3 cells; co-expression of dominant-negative GRK2, beta-arrestin 1-V53D, dynamin I-K44A; co-localization with transferrin in endosomes by fluorescence microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple dominant-negative constructs in two cell lines, co-localization with transferrin confirming clathrin pathway, single lab but multiple orthogonal approaches","pmids":["10347185"],"is_preprint":false},{"year":1999,"finding":"IL-8-induced internalization of CXCR1 is dependent on a carboxyl-terminal region containing six phosphorylation sites, whereas CXCR2 internalization is primarily regulated by a membrane-proximal C-terminal domain lacking phosphorylation sites; both receptors recycle back to the plasma membrane after ligand removal.","method":"HEK293 cell transfectants with CXCR1 and CXCR2 C-terminal deletion/mutation constructs; receptor internalization and recycling assays","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-mapping with multiple mutant constructs in a defined cell system, single lab, two orthogonal readouts (internalization and recycling)","pmids":["10623425"],"is_preprint":false},{"year":2004,"finding":"The CXCR1 N-terminal domain (N-domain) binds IL-8 with ~1 µM affinity in detergent micelles (mimicking membrane environment) versus ~20 µM in solution, and adopts a structured, membrane-interacting extended conformation in micelles; MGSA/GRO-alpha also binds the N-domain in micelles (~3 µM) but not in solution, indicating that conformational constraint by the membrane environment governs ligand selectivity at site I.","method":"Solution NMR and detergent-micelle NMR of the isolated CXCR1 N-domain peptide; binding affinity measurements with IL-8 and MGSA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural characterization combined with quantitative binding measurements in two environments, single lab with multiple orthogonal methods","pmids":["15133028"],"is_preprint":false},{"year":2005,"finding":"CXCR1 and CXCR2 form constitutive homo- and heterodimers with equal apparent affinities, initiated during protein biosynthesis prior to cell-surface delivery; these interactions are unaffected by IL-8 agonist treatment.","method":"Co-immunoprecipitation, single-cell FRET imaging, cell-surface time-resolved FRET, bioluminescence resonance energy transfer (BRET) saturation assays, ER-trapping strategy in HEK293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — four orthogonal biophysical methods including saturation BRET, co-IP, and ER trapping in a single rigorous study","pmids":["15946947"],"is_preprint":false},{"year":2005,"finding":"CXCR1 specifically activates PKCε (but not PKCα, -β1, or -β2) in human mononuclear phagocytes; PKCε mediates CXCR1-dependent receptor exocytosis and cross-desensitization of CCR5 but not phosphoinositide hydrolysis or peak Ca2+ mobilization.","method":"PKC isoform plasma membrane association assays, PKCε inhibitor peptide (εV1) expression, PKCε-/- peritoneal macrophages, CXCR1/CXCR2 chimeric receptor (ΔCxcr2) in RBL-2H3 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic knockout mice, pharmacological inhibitor, and chimeric receptor approach in one study; multiple orthogonal functional assays","pmids":["15905535"],"is_preprint":false},{"year":2007,"finding":"The second extracellular loop (2ECL) of CXCR2, specifically Asp199, is a critical structural determinant that drives CXCR2's rapid internalization kinetics relative to CXCR1; replacing CXCR2 Asp199 with CXCR1's valine (or swapping the entire 2ECL) converts CXCR2 internalization kinetics to match CXCR1.","method":"Chimeric and point-mutant receptor constructs (CXCR1/CXCR2 domain swaps and D199V, D199N mutations) stably expressed in RBL-2H3 cells; receptor binding, Ca2+ mobilization, phosphoinositide hydrolysis, phosphorylation, internalization, MAPK activation assays; structural modeling of 2ECL","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis combined with comprehensive receptor functional assays and structural modeling; multiple chimeric constructs tested systematically","pmids":["17204468"],"is_preprint":false},{"year":2009,"finding":"CXCL8 monomer (trapped non-associating form) is more potent than dimer for Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, and exocytosis; monomer more rapidly induces CXCR1 phosphorylation, desensitization, β-arrestin translocation, and internalization relative to dimer, while CXCR2 responds similarly to both forms; ERK phosphorylation is more sustained via CXCR2 than CXCR1.","method":"Trapped CXCL8 monomer (L25NMe) and non-dissociating dimer (R26C) used with human neutrophils and RBL cells stably expressing CXCR1 or CXCR2; Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, exocytosis, receptor phosphorylation, β-arrestin translocation, internalization, ERK phosphorylation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — engineered ligand variants with multiple orthogonal functional assays across receptor-expressing cell lines and primary neutrophils","pmids":["19667085"],"is_preprint":false},{"year":2009,"finding":"CXCR1 and CXCR2 form dynamic homo- and heterodimers in human neutrophils; CXCL8 stabilizes homodimers and promotes receptor internalization while altering heterodimeric complexes; receptor expression level and ligand activation regulate the balance between homo- and heterodimer states.","method":"FRET techniques in human neutrophils and co-expressing cell lines; receptor expression manipulation and ligand activation experiments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET in primary neutrophils and cell lines, single lab, multiple conditions tested","pmids":["19890050"],"is_preprint":false},{"year":2011,"finding":"CXCR1 undergoes rapid rotational diffusion about the bilayer normal in liquid-crystalline phospholipid bilayers; the N- and C-termini are mobile, while transmembrane helices and interhelical loops show restricted backbone dynamics; only ~13% of expected backbone amide resonances are observed in solution NMR due to limited local mobility of TM regions.","method":"Solution NMR (1H/15N HSQC, TROSY) in isotropic bicelles; solid-state NMR of magnetically aligned bilayers and unoriented bilayers with full-length and truncated CXCR1 constructs; 13C and 15N chemical shift powder patterns","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — solid-state and solution NMR with multiple constructs and labeling schemes, rigorous structural biophysical study","pmids":["21323370"],"is_preprint":false},{"year":2012,"finding":"The dual CXCR1/CXCR2 allosteric inhibitor DF2156A binds CXCR1 through a polar interaction network including a direct ionic bond with Lys99 on CXCR1, acting as a non-competitive allosteric inhibitor that blocks signal transduction leading to chemotaxis without altering natural ligand binding affinity.","method":"Radioligand binding assays, [35S]-GTPγS binding, chemotaxis assays with L1.2 transfectants and human leukocytes; mutagenesis/modeling of binding contacts (Lys99 on CXCR1, Asp293 on CXCR2)","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding and functional assays combined with structural modeling and identification of specific binding residues, single lab","pmids":["21718305"],"is_preprint":false},{"year":2016,"finding":"In Candida albicans systemic infection, CXCR1 (Cxcr1) is required for neutrophil degranulation (a cell-intrinsic effector function) and fungal killing in the kidney, but not for neutrophil trafficking from blood into infected tissue; the human CXCR1-T276 mutant allele similarly impairs neutrophil degranulation and antifungal killing.","method":"Cxcr1-/- mouse generation and systemic candidiasis model; survival, organ fungal burden, renal function, neutrophil trafficking and degranulation assays; human genetic variant (CXCR1-T276) functional analysis in patient neutrophils","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse phenotype rigorously dissected (trafficking vs. killing), corroborated by human genetic variant with functional consequence in patient neutrophils; two independent species/systems","pmids":["26791948"],"is_preprint":false},{"year":2016,"finding":"CXCR1 regulates pulmonary anti-Pseudomonas neutrophil responses by modulating reactive oxygen species production and Toll-like receptor 5 expression, functioning as a non-canonical chemokine receptor in innate host defense.","method":"Airway P. aeruginosa infection model in mice; in vivo bioluminescence imaging; neutrophil effector response assays; TLR5 expression analysis; human airway samples","journal":"Journal of innate immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo infection model with multiple functional readouts, mechanistic link to ROS and TLR5 established, single lab","pmids":["26950764"],"is_preprint":false},{"year":2010,"finding":"CXCR1 blockade in breast cancer depletes cancer stem cells and induces massive apoptosis of bulk tumor cells via FASL/FAS signaling; the mechanism involves the FAK/AKT/FOXO3A pathway; the CXCR1-specific inhibitor repertaxin recapitulates these effects in human breast cancer xenografts.","method":"CXCR1-specific blocking antibody and repertaxin treatment of breast cancer cell lines; ALDH/flow cytometry for CSC quantification; FASL/FAS apoptosis assays; FAK/AKT/FOXO3A pathway analysis; NOD/SCID xenograft models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple cell lines, two blocking agents, in vitro pathway analysis, and in vivo xenograft validation; multiple orthogonal methods in single study","pmids":["20051626"],"is_preprint":false},{"year":2007,"finding":"HIF-1 and NF-κB bind to the CXCR1 promoter and transcriptionally upregulate CXCR1 expression in response to hypoxia in prostate cancer cells; siRNA knockdown of HIF-1 or NF-κB, a HIF-1 dominant-negative, and pharmacological inhibitors all abrogate hypoxia-induced CXCR1 transcription.","method":"Chromatin immunoprecipitation (ChIP) demonstrating HIF-1 and NF-κB binding to CXCR1; siRNA knockdown; HIF-1 dominant-negative construct; pharmacological inhibitors; RT-PCR and immunoblotting in PC3 prostate cancer cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP directly demonstrates transcription factor binding to CXCR1 locus; multiple independent approaches (siRNA, dominant-negative, pharmacological) confirm mechanism; single lab","pmids":["17533374"],"is_preprint":false},{"year":2006,"finding":"Mouse CXCR1 (mCXCR1) is a functional receptor predominantly engaged by mouse GCP-2/CXCL6 and human IL-8/CXCL8 (but not by CXCR2-selective ligands ENA-78, NAP-2, GRO-α/β/γ, or CINC-1-3), as demonstrated by ligand binding, GTPγS exchange stimulation, and chemotaxis of mCXCR1-transfected cells.","method":"Cloning of mCXCR1 cDNA; radioligand binding assays; [35S]-GTPγS exchange assay; chemotaxis of mCXCR1-transfected cells; ligand panel screening","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — three independent functional assays (binding, GTPγS, chemotaxis) with a defined ligand panel; single lab but rigorous biochemical characterization","pmids":["17197447"],"is_preprint":false},{"year":2002,"finding":"Phagocytosis-induced downregulation of CXCR1 (and CXCR2) on human neutrophils occurs via metalloproteinase-dependent proteolytic degradation at the cell surface (not via internalization), as the metalloproteinase inhibitor 1,10-phenanthroline prevents reduction and confocal microscopy shows no internalization.","method":"Flow cytometry of CXCR1/CXCR2 surface expression after phagocytosis of opsonized yeast; metalloproteinase inhibitor treatment; confocal microscopy; Ca2+ response assays; RT-PCR for mRNA levels","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inhibitor pharmacology combined with confocal microscopy and mRNA analysis to distinguish proteolysis from internalization; single lab, multiple orthogonal methods","pmids":["12239185"],"is_preprint":false},{"year":2002,"finding":"CXCR1 internalization and recycling require actin-related kinase activity (sensitive to wortmannin); when both CXCR1 and CXCR2 are co-expressed, CXCR1 internalization is decreased compared to cells expressing only CXCR1, indicating receptor crosstalk during internalization.","method":"HEK293 transfectants with wild-type and chimeric/mutant CXCR1/CXCR2 constructs; wortmannin treatment; internalization and recycling assays; actin organization analysis","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-mapping and pharmacological inhibition with multiple receptor constructs; single lab","pmids":["12442335"],"is_preprint":false},{"year":2006,"finding":"CXCL8-induced chemotaxis via CXCR1 and CXCR2 is mediated through a pathway involving PI3K-dependent Cbl phosphorylation and Akt activation; Cbl overexpression (wild-type and G306E mutant, but not the RING-finger 70Z mutant) inhibits chemotaxis; kinase-dead Akt decreases both CXCL8-induced chemotaxis and Cbl phosphorylation; proteasome inhibitors block CXCR1/CXCR2 internalization.","method":"Cbl and Akt overexpression/dominant-negative in CXCR1/CXCR2-expressing L1.2 cells and human neutrophils; PI3K inhibitor LY294002; tyrphostin A9; proteasome inhibitors; co-immunoprecipitation of p85/Cbl; internalization assays","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple overexpression constructs and inhibitors, co-IP for Cbl-p85 interaction, single lab","pmids":["16798838"],"is_preprint":false},{"year":2016,"finding":"CXCR1 interacts specifically with accessory proteins REEP5 and REEP6 (CXCR2 does not); REEP5/6 are required for ligand-stimulated CXCR1 endocytosis and β-arrestin2 intracellular clustering but not for baseline CXCR1 membrane expression; REEP5/6 depletion impairs IL-8-stimulated ERK phosphorylation and actin polymerization downstream of CXCR1.","method":"Co-immunoprecipitation of CXCR1 with REEP5/6; overexpression and siRNA knockdown of REEP5/6; receptor internalization assays; β-arrestin2 clustering by immunofluorescence; ERK phosphorylation and actin polymerization assays; A549 xenograft model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus gain/loss-of-function for accessory protein interaction; single lab, multiple functional readouts","pmids":["27966653"],"is_preprint":false},{"year":1993,"finding":"The high-affinity IL-8 receptor gene (CXCR1/IL8RA) maps to chromosomal region 2q33-q36 and contains an intron in the 5' untranslated region; a pseudogene for the low-affinity IL-8 receptor (IL8RBP) was identified at a nearby locus.","method":"PCR-based cloning from genomic DNA; Southern blotting; in situ hybridization mapping to chromosome 2q33-q36; cDNA-genomic sequence comparison","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic mapping by in situ hybridization with sequence validation; foundational cloning study","pmids":["8486366"],"is_preprint":false},{"year":2017,"finding":"In zebrafish, cxcl8/cxcr1 signaling (expressed in endothelial cells) positively regulates HSPC colonization by increasing HSPC-endothelial 'cuddling', HSPC residency time, and mitotic rate in the caudal hematopoietic tissue; enhanced cxcr1 signaling increases CHT volume and induces cxcl12a expression; cxcr1 acts hematopoietic stem cell-nonautonomously to improve donor HSPC engraftment in parabiotic zebrafish.","method":"Single-cell tracking of fluorescent HSPCs in zebrafish CHT; cxcr1 gain/loss-of-function; parabiotic zebrafish engraftment assay; cxcl12a expression analysis","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live single-cell imaging, genetic manipulation, and parabiosis in zebrafish; ortholog study in vertebrate model, single lab","pmids":["28351983"],"is_preprint":false},{"year":2016,"finding":"CXCR1 (but not CXCR2) deficiency in hepatocytes reduces exosome release and abolishes packaging of neutral ceramidase and sphingosine kinase into exosomes, eliminating the hepatocyte proliferative effect of these exosomes; CXCR2 deficiency increases exosome release through elevated neutral sphingomyelinase (Nsm) activity and ceramide production.","method":"CXCR1-/- and CXCR2-/- hepatocytes; exosome quantification; neutral sphingomyelinase activity assay; ceramide measurement; hepatocyte proliferation assay with conditioned exosomes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout hepatocytes with multiple biochemical and functional readouts; single lab","pmids":["27551720"],"is_preprint":false},{"year":2018,"finding":"Natural posttranslational modifications of CXCL8 (N-terminal truncation to CXCL8(6-77) and citrullination to [Cit5]CXCL8) moderately enhance CXCR1 internalization and Gαi-dependent signaling, and increase β-arrestin 1 and 2 recruitment to CXCR1, without shifting the Gαi vs. β-arrestin signaling bias.","method":"Chemically synthesized CXCL8 variants; internalization assays with human neutrophils; Gαi-dependent signaling (HTRF); β-arrestin 1 and 2 recruitment assays to CXCR1 and CXCR2","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — chemically defined ligand variants tested across multiple receptor assay platforms; single lab","pmids":["30486423"],"is_preprint":false},{"year":2012,"finding":"HIV-1 matrix protein p17 binds CXCR1 (and CXCR2) on endothelial cells with high affinity and promotes capillary-like structure formation via ERK/Akt signaling; p17 is internalized into endothelial cell nuclei through receptor-mediated endocytosis.","method":"High-affinity binding assays of p17 to CXCR2 and CXCR1 on endothelial cells; tube formation assay with blocking antibodies; ERK/Akt signaling analysis; ex vivo and in vivo angiogenesis models; confocal microscopy of p17 nuclear localization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding assays, functional tube formation with receptor blocking, signaling pathway analysis, in vivo models; single lab, multiple methods","pmids":["22904195"],"is_preprint":false},{"year":2009,"finding":"CMV UL146-encoded vCXCL1 acts as a selective agonist of both CXCR1 and CXCR2 (affinities 44 nM and 5.6 nM respectively), activating calcium mobilization, phosphatidylinositol turnover, and chemotaxis, while not activating or blocking any of 16 other human chemokine receptors.","method":"Competition radioligand binding against CXCR1 and CXCR2; calcium mobilization; inositol triphosphate assay; chemotaxis assay in CHO, 300.19, COS7, and L1.2 cells expressing CXCR1 or CXCR2; panel of 18 chemokine receptor transfectants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — comprehensive receptor selectivity screen with four orthogonal functional assays and quantitative binding affinities; single lab, rigorous pharmacological characterization","pmids":["20044480"],"is_preprint":false},{"year":2023,"finding":"CXCR1 drives dendritic cell-dependent inflammation through a positive feedback loop involving CXCL5/CXCR1/HIF-1α signaling that directly regulates IL-6 and IL-12p70 production; DC-specific CXCR1 deletion suppresses inflammatory cytokine secretion and ameliorates EAE and LPS-induced ARDS.","method":"CXCR1 global and DC-specific knockout mice; EAE and ARDS models; antibody neutralization of CXCL5; cytokine ELISA; HIF-1α pathway analysis in DCs","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific knockout combined with two disease models and molecular pathway identification; single lab","pmids":["37709757"],"is_preprint":false}],"current_model":"CXCR1 is a G protein-coupled, seven-transmembrane chemokine receptor that binds IL-8/CXCL8 (and selectively GCP-2/CXCL6) through a two-site mechanism involving its membrane-constrained N-terminal domain (site I) and juxtamembrane domain (site II); upon ligand binding it activates Gi-independent Rho/Rho-kinase signaling leading to actin stress fiber formation, and triggers GRK2/β-arrestin/dynamin-dependent clathrin-mediated internalization that is regulated by C-terminal phosphorylation sites, with CXCR1 and CXCR2 constitutively forming homo- and heterodimers and showing distinct internalization kinetics governed by their respective second extracellular loops; CXCR1 uniquely activates PKCε (mediating exocytosis/degranulation and cross-desensitization of CCR5) and its expression is transcriptionally driven by HIF-1 and NF-κB under hypoxia; functionally, CXCR1-dependent neutrophil degranulation is essential for antifungal and anti-Pseudomonas host defense, and CXCR1 governs dendritic cell IL-6/IL-12 production via a CXCL5/HIF-1α feedback loop, while also regulating hepatocyte exosome composition and hematopoietic stem cell niche remodeling."},"narrative":{"mechanistic_narrative":"CXCR1 is a seven-transmembrane, G protein-coupled chemokine receptor that binds IL-8/CXCL8 and selectively the mouse ligand GCP-2/CXCL6 to drive neutrophil and leukocyte effector functions in innate host defense [PMID:17197447]. Ligand recognition follows a membrane-constrained two-site logic: the isolated N-terminal domain binds IL-8 with micromolar affinity and adopts a structured, membrane-interacting conformation only in a micelle/bilayer environment, a conformational constraint that governs ligand selectivity at site I [PMID:15133028], while the assembled receptor undergoes rapid rotational diffusion in the bilayer with mobile termini and dynamically restricted transmembrane helices [PMID:21323370]. Beyond canonical Gi coupling, CXCR1 activates a Gi-independent Rho/Rho-kinase cascade that builds actin stress fibers [PMID:11350788] and uniquely engages PKCε to mediate receptor exocytosis and cross-desensitization of CCR5 [PMID:15905535]. Agonist binding triggers GRK2/β-arrestin/dynamin-dependent clathrin-mediated internalization controlled by a C-terminal cluster of phosphorylation sites, with subsequent recycling to the surface [PMID:10347185, PMID:10623425]; CXCL8 monomer is the more potent driver of phosphorylation, β-arrestin recruitment and internalization than the dimer [PMID:19667085]. CXCR1 constitutively forms homo- and heterodimers with CXCR2 assembled during biosynthesis [PMID:15946947], and distinct second-extracellular-loop determinants set its slower internalization kinetics relative to CXCR2 [PMID:17204468]. Functionally, CXCR1 is required cell-intrinsically for neutrophil degranulation and microbial killing in candidiasis and anti-Pseudomonas pulmonary defense, independent of trafficking, with a human CXCR1-T276 variant impairing this effector arm [PMID:26791948, PMID:26950764]. Its expression is transcriptionally induced under hypoxia by HIF-1 and NF-κB binding to the CXCR1 promoter [PMID:17533374], and CXCR1 signaling extends to dendritic cell cytokine production via a CXCL5/HIF-1α feedback loop [PMID:37709757] and to breast cancer stem cell survival, where blockade triggers FAS/FASL apoptosis through the FAK/AKT/FOXO3A pathway [PMID:20051626].","teleology":[{"year":1993,"claim":"Establishing the genomic identity and locus of the high-affinity IL-8 receptor was the foundational step that defined CXCR1 as a discrete gene distinct from its low-affinity counterpart.","evidence":"PCR cloning, Southern blotting and in situ hybridization mapping to chromosome 2q33-q36","pmids":["8486366"],"confidence":"Medium","gaps":["Does not address receptor function or ligand specificity","No protein-level characterization"]},{"year":1999,"claim":"The internalization machinery and the C-terminal determinant controlling it were defined, distinguishing CXCR1 desensitization from CXCR2.","evidence":"Dominant-negative GRK2/β-arrestin1/dynamin constructs with CXCR1-GFP and C-terminal deletion mutants in HEK293/RBL-2H3 cells","pmids":["10347185","10623425"],"confidence":"High","gaps":["Specific phosphorylated residues among the six sites not individually mapped","Kinetics in primary neutrophils not assessed"]},{"year":2001,"claim":"CXCR1 was shown to drive a Gi-independent Rho/Rho-kinase signaling arm, separating its cytoskeletal output from CXCR2's Gi/Rac-mediated response.","evidence":"Dominant-negative Rho/Rac, C3 toxin, Y-27632, pertussis toxin and receptor-blocking antibodies in microvascular endothelial cells","pmids":["11350788"],"confidence":"High","gaps":["Upstream link between receptor and Rho activation not defined","Endothelial-specific vs leukocyte signaling not compared"]},{"year":2004,"claim":"NMR demonstrated that membrane environment constrains the N-domain conformation, providing the structural basis for site-I ligand selectivity.","evidence":"Solution and detergent-micelle NMR of the isolated CXCR1 N-domain with IL-8 and MGSA binding measurements","pmids":["15133028"],"confidence":"High","gaps":["Isolated peptide, not full-length receptor in native membrane","Site-II contribution not addressed here"]},{"year":2005,"claim":"CXCR1 was found to constitutively dimerize with itself and CXCR2 during biosynthesis, and to uniquely couple to PKCε for exocytosis and CCR5 cross-desensitization.","evidence":"BRET/FRET/co-IP with ER trapping in HEK293; PKCε inhibitor peptide, PKCε-/- macrophages and CXCR1/CXCR2 chimeras","pmids":["15946947","15905535"],"confidence":"High","gaps":["Functional consequence of heterodimerization on signaling output not fully resolved","PKCε activation mechanism downstream of receptor unknown"]},{"year":2006,"claim":"Cloning of mouse CXCR1 established its ligand specificity (GCP-2/CXCL6 and human IL-8) and validated a tractable ortholog for in vivo study.","evidence":"Radioligand binding, GTPγS exchange and chemotaxis of mCXCR1 transfectants against a ligand panel","pmids":["17197447"],"confidence":"High","gaps":["Endogenous mouse ligand in vivo not defined","Receptor signaling differences between species not characterized"]},{"year":2007,"claim":"The second extracellular loop, and specifically Asp199 in CXCR2, was identified as the structural switch governing the divergent internalization kinetics of the two receptors.","evidence":"CXCR1/CXCR2 domain swaps and D199V/D199N point mutants with comprehensive functional assays in RBL-2H3 cells","pmids":["17204468"],"confidence":"High","gaps":["How 2ECL identity is transmitted to the endocytic machinery is unresolved","Physiological relevance of kinetic difference not tested"]},{"year":2007,"claim":"Hypoxic transcriptional control of CXCR1 was established by direct HIF-1 and NF-κB binding to its promoter.","evidence":"ChIP, siRNA, HIF-1 dominant-negative and pharmacological inhibitors in PC3 prostate cancer cells","pmids":["17533374"],"confidence":"High","gaps":["Promoter element coordinates not detailed","Relevance to neutrophil/immune cell expression not tested"]},{"year":2009,"claim":"Ligand oligomeric state was shown to bias CXCR1 responses, with the CXCL8 monomer driving more rapid phosphorylation, β-arrestin translocation and internalization than the dimer.","evidence":"Trapped CXCL8 monomer (L25NMe) and dimer (R26C) across neutrophils and CXCR1/CXCR2 RBL cells with multiple functional readouts; dynamic FRET dimer analysis","pmids":["19667085","19890050"],"confidence":"High","gaps":["Structural basis for monomer preference at CXCR1 not defined","Quantitative dimer/monomer balance in vivo unknown"]},{"year":2011,"claim":"Solid-state and solution NMR of full-length CXCR1 in bilayers defined its rotational dynamics and the restricted mobility of transmembrane helices in a native-like environment.","evidence":"Solution NMR in bicelles and solid-state NMR of aligned bilayers with full-length and truncated constructs","pmids":["21323370"],"confidence":"High","gaps":["No high-resolution atomic structure of the receptor","Ligand-bound dynamics not captured"]},{"year":2016,"claim":"Genetic dissection in mice and a human variant showed CXCR1's host-defense role lies in cell-intrinsic neutrophil degranulation and microbial killing, not trafficking.","evidence":"Cxcr1-/- mouse candidiasis and Pseudomonas airway models, ROS/TLR5 analysis, and CXCR1-T276 patient neutrophil function","pmids":["26791948","26950764"],"confidence":"High","gaps":["Molecular link from CXCR1 to degranulation/ROS not fully mapped","Mechanism of TLR5 modulation unknown"]},{"year":2016,"claim":"Accessory proteins REEP5/6 were identified as CXCR1-selective partners required for ligand-stimulated endocytosis and downstream signaling.","evidence":"Co-IP, overexpression and siRNA of REEP5/6 with internalization, β-arrestin2 clustering, ERK and actin assays; A549 xenograft","pmids":["27966653"],"confidence":"Medium","gaps":["Structural basis of CXCR1-REEP interaction unknown","Single-lab co-IP without reciprocal in vivo validation"]},{"year":2016,"claim":"CXCR1 was shown to control hepatocyte exosome biogenesis and cargo packaging, extending its role beyond chemotaxis to vesicle-mediated intercellular signaling.","evidence":"CXCR1-/- and CXCR2-/- hepatocytes with exosome quantification, sphingomyelinase/ceramide assays and proliferation readouts","pmids":["27551720"],"confidence":"Medium","gaps":["Signaling pathway from receptor to exosome machinery undefined","Ligand driving this hepatocyte function unknown"]},{"year":2010,"claim":"CXCR1 blockade was shown to selectively kill breast cancer stem cells, defining a non-immune oncogenic function via FAS/FASL and FAK/AKT/FOXO3A signaling.","evidence":"Repertaxin and blocking antibody in breast cancer cell lines, ALDH/flow CSC quantification, pathway analysis and NOD/SCID xenografts","pmids":["20051626"],"confidence":"High","gaps":["Endogenous ligand sustaining CSC survival not identified","Direct receptor-to-FAK coupling mechanism unresolved"]},{"year":2012,"claim":"Pathogen-derived and pharmacological ligands clarified CXCR1's druggable allosteric pocket and its exploitation by viral mimics.","evidence":"DF2156A allosteric inhibitor binding via Lys99 (radioligand/GTPγS/chemotaxis with modeling) and HIV-1 p17 high-affinity binding driving angiogenesis via ERK/Akt","pmids":["21718305","22904195"],"confidence":"Medium","gaps":["Allosteric mechanism not validated structurally","Physiological consequence of p17 engagement in HIV infection unclear"]},{"year":2018,"claim":"Posttranslationally modified CXCL8 forms were shown to modulate CXCR1 internalization and signaling magnitude without altering the Gαi/β-arrestin bias.","evidence":"Synthetic CXCL8(6-77) and [Cit5]CXCL8 variants in neutrophil internalization, HTRF Gαi and β-arrestin recruitment assays","pmids":["30486423"],"confidence":"Medium","gaps":["In vivo abundance and relevance of modified ligands unknown","Structural basis of altered potency undefined"]},{"year":2023,"claim":"DC-specific deletion established a CXCL5/CXCR1/HIF-1α feedback loop controlling IL-6 and IL-12 production and inflammatory disease severity.","evidence":"Global and DC-specific CXCR1 knockout mice in EAE and ARDS models with CXCL5 neutralization and HIF-1α pathway analysis","pmids":["37709757"],"confidence":"Medium","gaps":["Direct CXCR1-HIF-1α coupling mechanism in DCs not resolved","Whether feedback operates in human DCs untested"]},{"year":null,"claim":"How CXCR1's distinct downstream effectors (Rho/Rho-kinase, PKCε, REEP5/6, exosome machinery) are selectively engaged by a single receptor, and what governs ligand-, dimer-, and tissue-specific output, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution ligand-bound structure to rationalize biased signaling","Mechanistic link from receptor to tissue-specific effector programs (degranulation, exosomes, CSC survival) not unified","Endogenous human ligand specificity in each context incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,15,25]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,15]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[24,25]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,9]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[1,22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,12,26]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1,2,19]}],"complexes":["CXCR1-CXCR2 homo/heterodimer"],"partners":["CXCR2","GRK2","ARRB1","DNM1","PRKCE","REEP5","REEP6","CBL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25024","full_name":"C-X-C chemokine receptor type 1","aliases":["CDw128a","High affinity interleukin-8 receptor A","IL-8R A","IL-8 receptor type 1"],"length_aa":350,"mass_kda":39.8,"function":"Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor (PubMed:1840701). Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:8662698)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P25024/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCR1","total_profiled":1310},"omim":[{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"153620","title":"MACROPHAGE MIGRATION INHIBITORY FACTOR; MIF","url":"https://www.omim.org/entry/153620"},{"mim_id":"146929","title":"CHEMOKINE, CXC MOTIF, RECEPTOR 1; CXCR1","url":"https://www.omim.org/entry/146929"},{"mim_id":"146928","title":"CHEMOKINE, CXC MOTIF, RECEPTOR 2; CXCR2","url":"https://www.omim.org/entry/146928"},{"mim_id":"138965","title":"CHEMOKINE, CXC MOTIF, LIGAND 6; CXCL6","url":"https://www.omim.org/entry/138965"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":12.3},{"tissue":"lymphoid tissue","ntpm":38.8}],"url":"https://www.proteinatlas.org/search/CXCR1"},"hgnc":{"alias_symbol":["CKR-1","CDw128a","CD181"],"prev_symbol":["CMKAR1","IL8RA"]},"alphafold":{"accession":"P25024","domains":[{"cath_id":"1.20.1070.10","chopping":"35-313","consensus_level":"high","plddt":84.4139,"start":35,"end":313}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25024","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25024-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25024-F1-predicted_aligned_error_v6.png","plddt_mean":78.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCR1","jax_strain_url":"https://www.jax.org/strain/search?query=CXCR1"},"sequence":{"accession":"P25024","fasta_url":"https://rest.uniprot.org/uniprotkb/P25024.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25024/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25024"}},"corpus_meta":[{"pmid":"32289253","id":"PMC_32289253","title":"CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32289253","citation_count":655,"is_preprint":false},{"pmid":"28529637","id":"PMC_28529637","title":"Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28529637","citation_count":620,"is_preprint":false},{"pmid":"20051626","id":"PMC_20051626","title":"CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20051626","citation_count":593,"is_preprint":false},{"pmid":"27578214","id":"PMC_27578214","title":"The CXCL8-CXCR1/2 pathways in cancer.","date":"2016","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27578214","citation_count":523,"is_preprint":false},{"pmid":"31488817","id":"PMC_31488817","title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31488817","citation_count":326,"is_preprint":false},{"pmid":"31848188","id":"PMC_31848188","title":"Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31848188","citation_count":240,"is_preprint":false},{"pmid":"11350788","id":"PMC_11350788","title":"IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11350788","citation_count":224,"is_preprint":false},{"pmid":"17533374","id":"PMC_17533374","title":"HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17533374","citation_count":176,"is_preprint":false},{"pmid":"17197447","id":"PMC_17197447","title":"Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17197447","citation_count":175,"is_preprint":false},{"pmid":"9973513","id":"PMC_9973513","title":"Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9973513","citation_count":174,"is_preprint":false},{"pmid":"19667085","id":"PMC_19667085","title":"Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19667085","citation_count":159,"is_preprint":false},{"pmid":"22996693","id":"PMC_22996693","title":"CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22996693","citation_count":124,"is_preprint":false},{"pmid":"15946947","id":"PMC_15946947","title":"The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15946947","citation_count":107,"is_preprint":false},{"pmid":"10347185","id":"PMC_10347185","title":"beta-arrestins regulate interleukin-8-induced CXCR1 internalization.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10347185","citation_count":106,"is_preprint":false},{"pmid":"35011369","id":"PMC_35011369","title":"Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35011369","citation_count":101,"is_preprint":false},{"pmid":"19401689","id":"PMC_19401689","title":"CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19401689","citation_count":95,"is_preprint":false},{"pmid":"36585453","id":"PMC_36585453","title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.","date":"2022","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36585453","citation_count":94,"is_preprint":false},{"pmid":"15133028","id":"PMC_15133028","title":"Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15133028","citation_count":94,"is_preprint":false},{"pmid":"34353854","id":"PMC_34353854","title":"Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34353854","citation_count":92,"is_preprint":false},{"pmid":"16393674","id":"PMC_16393674","title":"Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma.","date":"2006","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16393674","citation_count":91,"is_preprint":false},{"pmid":"34893315","id":"PMC_34893315","title":"Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis.","date":"2021","source":"British journal of anaesthesia","url":"https://pubmed.ncbi.nlm.nih.gov/34893315","citation_count":88,"is_preprint":false},{"pmid":"30086759","id":"PMC_30086759","title":"IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma.","date":"2018","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/30086759","citation_count":84,"is_preprint":false},{"pmid":"22904195","id":"PMC_22904195","title":"HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22904195","citation_count":83,"is_preprint":false},{"pmid":"11356265","id":"PMC_11356265","title":"Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells.","date":"2001","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11356265","citation_count":78,"is_preprint":false},{"pmid":"25315007","id":"PMC_25315007","title":"CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25315007","citation_count":77,"is_preprint":false},{"pmid":"14713106","id":"PMC_14713106","title":"Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype.","date":"2003","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/14713106","citation_count":76,"is_preprint":false},{"pmid":"10623425","id":"PMC_10623425","title":"Differential modes of regulation of cxc chemokine-induced internalization and recycling of human CXCR1 and CXCR2.","date":"1999","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/10623425","citation_count":74,"is_preprint":false},{"pmid":"26791948","id":"PMC_26791948","title":"CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival.","date":"2016","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26791948","citation_count":72,"is_preprint":false},{"pmid":"15294933","id":"PMC_15294933","title":"Cutting edge: expression of chemokine receptor CXCR1 on human effector CD8+ T cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15294933","citation_count":72,"is_preprint":false},{"pmid":"32188703","id":"PMC_32188703","title":"Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32188703","citation_count":71,"is_preprint":false},{"pmid":"21749879","id":"PMC_21749879","title":"CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation.","date":"2011","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21749879","citation_count":69,"is_preprint":false},{"pmid":"9725262","id":"PMC_9725262","title":"Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9725262","citation_count":69,"is_preprint":false},{"pmid":"21718305","id":"PMC_21718305","title":"Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21718305","citation_count":66,"is_preprint":false},{"pmid":"26517518","id":"PMC_26517518","title":"Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26517518","citation_count":62,"is_preprint":false},{"pmid":"18826477","id":"PMC_18826477","title":"TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections.","date":"2008","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/18826477","citation_count":61,"is_preprint":false},{"pmid":"20044480","id":"PMC_20044480","title":"The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20044480","citation_count":60,"is_preprint":false},{"pmid":"17296422","id":"PMC_17296422","title":"Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis.","date":"2007","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/17296422","citation_count":59,"is_preprint":false},{"pmid":"27557518","id":"PMC_27557518","title":"IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27557518","citation_count":54,"is_preprint":false},{"pmid":"16084593","id":"PMC_16084593","title":"A homolog of the human chemokine receptor CXCR1 is expressed in the mouse.","date":"2005","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16084593","citation_count":54,"is_preprint":false},{"pmid":"15967374","id":"PMC_15967374","title":"Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15967374","citation_count":53,"is_preprint":false},{"pmid":"18552386","id":"PMC_18552386","title":"Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/18552386","citation_count":51,"is_preprint":false},{"pmid":"35908611","id":"PMC_35908611","title":"Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases.","date":"2022","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35908611","citation_count":50,"is_preprint":false},{"pmid":"20230195","id":"PMC_20230195","title":"Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/20230195","citation_count":50,"is_preprint":false},{"pmid":"28423567","id":"PMC_28423567","title":"CXCR1/2 pathways in paclitaxel-induced neuropathic pain.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28423567","citation_count":48,"is_preprint":false},{"pmid":"19585580","id":"PMC_19585580","title":"Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19585580","citation_count":48,"is_preprint":false},{"pmid":"34097917","id":"PMC_34097917","title":"The IL-8-CXCR1/2 axis contributes to diabetic kidney disease.","date":"2021","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/34097917","citation_count":46,"is_preprint":false},{"pmid":"37249756","id":"PMC_37249756","title":"Therapeutic inhibition of CXCR1/2: where do we stand?","date":"2023","source":"Internal and emergency medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37249756","citation_count":45,"is_preprint":false},{"pmid":"17204468","id":"PMC_17204468","title":"CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17204468","citation_count":45,"is_preprint":false},{"pmid":"34426905","id":"PMC_34426905","title":"An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34426905","citation_count":44,"is_preprint":false},{"pmid":"19890050","id":"PMC_19890050","title":"Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19890050","citation_count":44,"is_preprint":false},{"pmid":"20089160","id":"PMC_20089160","title":"CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous leishmaniasis in Brazil: a case-control and family-based study.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20089160","citation_count":44,"is_preprint":false},{"pmid":"28351983","id":"PMC_28351983","title":"CXCR1 remodels the vascular niche to promote hematopoietic stem and progenitor cell engraftment.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28351983","citation_count":43,"is_preprint":false},{"pmid":"21323370","id":"PMC_21323370","title":"Local and global dynamics of the G protein-coupled receptor CXCR1.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21323370","citation_count":43,"is_preprint":false},{"pmid":"22152684","id":"PMC_22152684","title":"Decreased CXCR1 and CXCR2 expression on neutrophils in anti-neutrophil cytoplasmic autoantibody-associated vasculitides potentially increases neutrophil adhesion and impairs migration.","date":"2011","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22152684","citation_count":42,"is_preprint":false},{"pmid":"30984000","id":"PMC_30984000","title":"Activation of CXCL6/CXCR1/2 Axis Promotes the Growth and Metastasis of Osteosarcoma Cells in vitro and in vivo.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30984000","citation_count":41,"is_preprint":false},{"pmid":"12239185","id":"PMC_12239185","title":"Phagocytosing neutrophils down-regulate the expression of chemokine receptors CXCR1 and CXCR2.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12239185","citation_count":38,"is_preprint":false},{"pmid":"31410218","id":"PMC_31410218","title":"New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31410218","citation_count":38,"is_preprint":false},{"pmid":"15265017","id":"PMC_15265017","title":"Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2.","date":"2004","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15265017","citation_count":38,"is_preprint":false},{"pmid":"32391006","id":"PMC_32391006","title":"Structural Insights Into How Proteoglycans Determine Chemokine-CXCR1/CXCR2 Interactions: Progress and Challenges.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32391006","citation_count":37,"is_preprint":false},{"pmid":"16541017","id":"PMC_16541017","title":"Expression of the chemokine receptor CXCR1 in human glomerular diseases.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16541017","citation_count":37,"is_preprint":false},{"pmid":"30883740","id":"PMC_30883740","title":"IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30883740","citation_count":37,"is_preprint":false},{"pmid":"15905535","id":"PMC_15905535","title":"Cross-desensitization among CXCR1, CXCR2, and CCR5: role of protein kinase C-epsilon.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905535","citation_count":37,"is_preprint":false},{"pmid":"31516616","id":"PMC_31516616","title":"Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31516616","citation_count":36,"is_preprint":false},{"pmid":"25031742","id":"PMC_25031742","title":"High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031742","citation_count":35,"is_preprint":false},{"pmid":"24965032","id":"PMC_24965032","title":"The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour.","date":"2014","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24965032","citation_count":34,"is_preprint":false},{"pmid":"30738331","id":"PMC_30738331","title":"Disrupting Inflammation-Associated CXCL8-CXCR1 Signaling Inhibits Tumorigenicity Initiated by Sporadic- and Colitis-Colon Cancer Stem Cells.","date":"2019","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30738331","citation_count":34,"is_preprint":false},{"pmid":"30797069","id":"PMC_30797069","title":"Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling.","date":"2019","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30797069","citation_count":34,"is_preprint":false},{"pmid":"17433017","id":"PMC_17433017","title":"Identification of single nucleotide polymorphisms in the bovine CCL2, IL8, CCR2 and IL8RA genes and their association with health and production in Canadian Holsteins.","date":"2007","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17433017","citation_count":33,"is_preprint":false},{"pmid":"26391645","id":"PMC_26391645","title":"CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26391645","citation_count":33,"is_preprint":false},{"pmid":"16339057","id":"PMC_16339057","title":"Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections.","date":"2005","source":"Clinical and diagnostic laboratory immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16339057","citation_count":33,"is_preprint":false},{"pmid":"32800946","id":"PMC_32800946","title":"KLF2 regulates neutrophil migration by modulating CXCR1 and CXCR2 in asthma.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32800946","citation_count":32,"is_preprint":false},{"pmid":"21036625","id":"PMC_21036625","title":"CXCR1 and CXCR2 are novel mechano-sensors mediating laminar shear stress-induced endothelial cell migration.","date":"2010","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/21036625","citation_count":32,"is_preprint":false},{"pmid":"26473526","id":"PMC_26473526","title":"Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.","date":"2016","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/26473526","citation_count":32,"is_preprint":false},{"pmid":"27551720","id":"PMC_27551720","title":"Chemokine Receptors, CXCR1 and CXCR2, Differentially Regulate Exosome Release in Hepatocytes.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27551720","citation_count":29,"is_preprint":false},{"pmid":"16798838","id":"PMC_16798838","title":"Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis.","date":"2006","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16798838","citation_count":28,"is_preprint":false},{"pmid":"27966653","id":"PMC_27966653","title":"The accessory proteins REEP5 and REEP6 refine CXCR1-mediated cellular responses and lung cancer progression.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27966653","citation_count":27,"is_preprint":false},{"pmid":"26275440","id":"PMC_26275440","title":"The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions.","date":"2015","source":"Current diabetes reports","url":"https://pubmed.ncbi.nlm.nih.gov/26275440","citation_count":26,"is_preprint":false},{"pmid":"37062329","id":"PMC_37062329","title":"Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37062329","citation_count":26,"is_preprint":false},{"pmid":"26950764","id":"PMC_26950764","title":"CXCR1 Regulates Pulmonary Anti-Pseudomonas Host Defense.","date":"2016","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26950764","citation_count":26,"is_preprint":false},{"pmid":"15557597","id":"PMC_15557597","title":"Downregulation of CXCR1 and CXCR2 expression on human neutrophils by Helicobacter pylori: a new pathomechanism in H. pylori infection?","date":"2004","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15557597","citation_count":26,"is_preprint":false},{"pmid":"37760523","id":"PMC_37760523","title":"The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML).","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37760523","citation_count":25,"is_preprint":false},{"pmid":"30123110","id":"PMC_30123110","title":"Role of CXCR1 and Interleukin-8 in Methamphetamine-Induced Neuronal Apoptosis.","date":"2018","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30123110","citation_count":25,"is_preprint":false},{"pmid":"8486366","id":"PMC_8486366","title":"The high-affinity interleukin 8 receptor gene (IL8RA) maps to the 2q33-q36 region of the human genome: cloning of a pseudogene (IL8RBP) for the low-affinity receptor.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8486366","citation_count":23,"is_preprint":false},{"pmid":"22325052","id":"PMC_22325052","title":"Genetic variations of interleukin-8, CXCR1 and CXCR2 genes and risk of acute pyelonephritis in children.","date":"2012","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22325052","citation_count":23,"is_preprint":false},{"pmid":"22088968","id":"PMC_22088968","title":"CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease.","date":"2011","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/22088968","citation_count":23,"is_preprint":false},{"pmid":"33582208","id":"PMC_33582208","title":"CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.","date":"2021","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33582208","citation_count":23,"is_preprint":false},{"pmid":"34014914","id":"PMC_34014914","title":"Conformational plasticity and dynamic interactions of the N-terminal domain of the chemokine receptor CXCR1.","date":"2021","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/34014914","citation_count":22,"is_preprint":false},{"pmid":"35392239","id":"PMC_35392239","title":"The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 low Mice.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35392239","citation_count":21,"is_preprint":false},{"pmid":"31573846","id":"PMC_31573846","title":"The antagonist of CXCR1 and CXCR2 protects db/db mice from metabolic diseases through modulating inflammation.","date":"2019","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31573846","citation_count":21,"is_preprint":false},{"pmid":"12065915","id":"PMC_12065915","title":"Expression of the interleukin-8 receptors CXCR1 and CXCR2 on cord-blood-derived cultured human mast cells.","date":"2002","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12065915","citation_count":21,"is_preprint":false},{"pmid":"32052443","id":"PMC_32052443","title":"MMP9, CXCR1, TLR6, and MPO participant in the progression of coronary artery disease.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32052443","citation_count":19,"is_preprint":false},{"pmid":"12442335","id":"PMC_12442335","title":"Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12442335","citation_count":19,"is_preprint":false},{"pmid":"34120407","id":"PMC_34120407","title":"MiR-144-induced KLF2 inhibition and NF-kappaB/CXCR1 activation promote neutrophil extracellular trap-induced transfusion-related acute lung injury.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34120407","citation_count":19,"is_preprint":false},{"pmid":"14688334","id":"PMC_14688334","title":"CXCR1+CD4+ T cells in human allergic disease.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14688334","citation_count":19,"is_preprint":false},{"pmid":"39048127","id":"PMC_39048127","title":"A narrative review of chemokine receptors CXCR1 and CXCR2 and their role in acute respiratory distress syndrome.","date":"2024","source":"European respiratory review : an official journal of the European Respiratory Society","url":"https://pubmed.ncbi.nlm.nih.gov/39048127","citation_count":18,"is_preprint":false},{"pmid":"36325326","id":"PMC_36325326","title":"CXCR1 and its downstream NF-κB inflammation signaling pathway as a key target of Guanxinning injection for myocardial ischemia/reperfusion injury.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36325326","citation_count":18,"is_preprint":false},{"pmid":"30486423","id":"PMC_30486423","title":"Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30486423","citation_count":18,"is_preprint":false},{"pmid":"21915051","id":"PMC_21915051","title":"Elevated expression of the interleukin-8 receptors CXCR1 and CXCR2 in peripheral blood cells in obstructive coronary artery disease.","date":"2011","source":"Coronary artery disease","url":"https://pubmed.ncbi.nlm.nih.gov/21915051","citation_count":18,"is_preprint":false},{"pmid":"37709757","id":"PMC_37709757","title":"CXCR1 drives the pathogenesis of EAE and ARDS via boosting dendritic cells-dependent inflammation.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37709757","citation_count":17,"is_preprint":false},{"pmid":"35634429","id":"PMC_35634429","title":"Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma.","date":"2022","source":"Liver cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35634429","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56657,"output_tokens":7819,"usd":0.143628,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16942,"output_tokens":5330,"usd":0.10898,"stage2_stop_reason":"end_turn"},"total_usd":0.252608,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"IL-8 activation of CXCR1 on microvascular endothelial cells induces early-phase actin stress fiber formation via a Rho/Rho-kinase signaling cascade (blocked by C3 botulinum toxin and Y-27632, but not pertussis toxin), distinct from CXCR2-mediated later-phase cell retraction via Gi and Rac.\",\n      \"method\": \"Dominant-negative Rho and Rac overexpression, C3 botulinum toxin, pertussis toxin treatment, CXCR1/CXCR2-specific blocking antibodies in microvascular endothelial cells\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Moderate — multiple pharmacological and genetic tools (dominant negatives, bacterial toxins, blocking antibodies) in a single study with clear mechanistic resolution of CXCR1 vs CXCR2 signaling arms\",\n      \"pmids\": [\"11350788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Agonist-induced CXCR1 internalization requires GRK2, beta-arrestins, and dynamin, and proceeds via clathrin-coated vesicles; dominant-negative beta-arrestin 1-V53D and dynamin I-K44A both block CXCR1-GFP internalization.\",\n      \"method\": \"CXCR1-GFP fusion protein expression in HEK293 and RBL-2H3 cells; co-expression of dominant-negative GRK2, beta-arrestin 1-V53D, dynamin I-K44A; co-localization with transferrin in endosomes by fluorescence microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple dominant-negative constructs in two cell lines, co-localization with transferrin confirming clathrin pathway, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"10347185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IL-8-induced internalization of CXCR1 is dependent on a carboxyl-terminal region containing six phosphorylation sites, whereas CXCR2 internalization is primarily regulated by a membrane-proximal C-terminal domain lacking phosphorylation sites; both receptors recycle back to the plasma membrane after ligand removal.\",\n      \"method\": \"HEK293 cell transfectants with CXCR1 and CXCR2 C-terminal deletion/mutation constructs; receptor internalization and recycling assays\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-mapping with multiple mutant constructs in a defined cell system, single lab, two orthogonal readouts (internalization and recycling)\",\n      \"pmids\": [\"10623425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The CXCR1 N-terminal domain (N-domain) binds IL-8 with ~1 µM affinity in detergent micelles (mimicking membrane environment) versus ~20 µM in solution, and adopts a structured, membrane-interacting extended conformation in micelles; MGSA/GRO-alpha also binds the N-domain in micelles (~3 µM) but not in solution, indicating that conformational constraint by the membrane environment governs ligand selectivity at site I.\",\n      \"method\": \"Solution NMR and detergent-micelle NMR of the isolated CXCR1 N-domain peptide; binding affinity measurements with IL-8 and MGSA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural characterization combined with quantitative binding measurements in two environments, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15133028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCR1 and CXCR2 form constitutive homo- and heterodimers with equal apparent affinities, initiated during protein biosynthesis prior to cell-surface delivery; these interactions are unaffected by IL-8 agonist treatment.\",\n      \"method\": \"Co-immunoprecipitation, single-cell FRET imaging, cell-surface time-resolved FRET, bioluminescence resonance energy transfer (BRET) saturation assays, ER-trapping strategy in HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — four orthogonal biophysical methods including saturation BRET, co-IP, and ER trapping in a single rigorous study\",\n      \"pmids\": [\"15946947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCR1 specifically activates PKCε (but not PKCα, -β1, or -β2) in human mononuclear phagocytes; PKCε mediates CXCR1-dependent receptor exocytosis and cross-desensitization of CCR5 but not phosphoinositide hydrolysis or peak Ca2+ mobilization.\",\n      \"method\": \"PKC isoform plasma membrane association assays, PKCε inhibitor peptide (εV1) expression, PKCε-/- peritoneal macrophages, CXCR1/CXCR2 chimeric receptor (ΔCxcr2) in RBL-2H3 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic knockout mice, pharmacological inhibitor, and chimeric receptor approach in one study; multiple orthogonal functional assays\",\n      \"pmids\": [\"15905535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The second extracellular loop (2ECL) of CXCR2, specifically Asp199, is a critical structural determinant that drives CXCR2's rapid internalization kinetics relative to CXCR1; replacing CXCR2 Asp199 with CXCR1's valine (or swapping the entire 2ECL) converts CXCR2 internalization kinetics to match CXCR1.\",\n      \"method\": \"Chimeric and point-mutant receptor constructs (CXCR1/CXCR2 domain swaps and D199V, D199N mutations) stably expressed in RBL-2H3 cells; receptor binding, Ca2+ mobilization, phosphoinositide hydrolysis, phosphorylation, internalization, MAPK activation assays; structural modeling of 2ECL\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis combined with comprehensive receptor functional assays and structural modeling; multiple chimeric constructs tested systematically\",\n      \"pmids\": [\"17204468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL8 monomer (trapped non-associating form) is more potent than dimer for Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, and exocytosis; monomer more rapidly induces CXCR1 phosphorylation, desensitization, β-arrestin translocation, and internalization relative to dimer, while CXCR2 responds similarly to both forms; ERK phosphorylation is more sustained via CXCR2 than CXCR1.\",\n      \"method\": \"Trapped CXCL8 monomer (L25NMe) and non-dissociating dimer (R26C) used with human neutrophils and RBL cells stably expressing CXCR1 or CXCR2; Ca2+ mobilization, phosphoinositide hydrolysis, chemotaxis, exocytosis, receptor phosphorylation, β-arrestin translocation, internalization, ERK phosphorylation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — engineered ligand variants with multiple orthogonal functional assays across receptor-expressing cell lines and primary neutrophils\",\n      \"pmids\": [\"19667085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCR1 and CXCR2 form dynamic homo- and heterodimers in human neutrophils; CXCL8 stabilizes homodimers and promotes receptor internalization while altering heterodimeric complexes; receptor expression level and ligand activation regulate the balance between homo- and heterodimer states.\",\n      \"method\": \"FRET techniques in human neutrophils and co-expressing cell lines; receptor expression manipulation and ligand activation experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET in primary neutrophils and cell lines, single lab, multiple conditions tested\",\n      \"pmids\": [\"19890050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCR1 undergoes rapid rotational diffusion about the bilayer normal in liquid-crystalline phospholipid bilayers; the N- and C-termini are mobile, while transmembrane helices and interhelical loops show restricted backbone dynamics; only ~13% of expected backbone amide resonances are observed in solution NMR due to limited local mobility of TM regions.\",\n      \"method\": \"Solution NMR (1H/15N HSQC, TROSY) in isotropic bicelles; solid-state NMR of magnetically aligned bilayers and unoriented bilayers with full-length and truncated CXCR1 constructs; 13C and 15N chemical shift powder patterns\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — solid-state and solution NMR with multiple constructs and labeling schemes, rigorous structural biophysical study\",\n      \"pmids\": [\"21323370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The dual CXCR1/CXCR2 allosteric inhibitor DF2156A binds CXCR1 through a polar interaction network including a direct ionic bond with Lys99 on CXCR1, acting as a non-competitive allosteric inhibitor that blocks signal transduction leading to chemotaxis without altering natural ligand binding affinity.\",\n      \"method\": \"Radioligand binding assays, [35S]-GTPγS binding, chemotaxis assays with L1.2 transfectants and human leukocytes; mutagenesis/modeling of binding contacts (Lys99 on CXCR1, Asp293 on CXCR2)\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding and functional assays combined with structural modeling and identification of specific binding residues, single lab\",\n      \"pmids\": [\"21718305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In Candida albicans systemic infection, CXCR1 (Cxcr1) is required for neutrophil degranulation (a cell-intrinsic effector function) and fungal killing in the kidney, but not for neutrophil trafficking from blood into infected tissue; the human CXCR1-T276 mutant allele similarly impairs neutrophil degranulation and antifungal killing.\",\n      \"method\": \"Cxcr1-/- mouse generation and systemic candidiasis model; survival, organ fungal burden, renal function, neutrophil trafficking and degranulation assays; human genetic variant (CXCR1-T276) functional analysis in patient neutrophils\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse phenotype rigorously dissected (trafficking vs. killing), corroborated by human genetic variant with functional consequence in patient neutrophils; two independent species/systems\",\n      \"pmids\": [\"26791948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCR1 regulates pulmonary anti-Pseudomonas neutrophil responses by modulating reactive oxygen species production and Toll-like receptor 5 expression, functioning as a non-canonical chemokine receptor in innate host defense.\",\n      \"method\": \"Airway P. aeruginosa infection model in mice; in vivo bioluminescence imaging; neutrophil effector response assays; TLR5 expression analysis; human airway samples\",\n      \"journal\": \"Journal of innate immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo infection model with multiple functional readouts, mechanistic link to ROS and TLR5 established, single lab\",\n      \"pmids\": [\"26950764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCR1 blockade in breast cancer depletes cancer stem cells and induces massive apoptosis of bulk tumor cells via FASL/FAS signaling; the mechanism involves the FAK/AKT/FOXO3A pathway; the CXCR1-specific inhibitor repertaxin recapitulates these effects in human breast cancer xenografts.\",\n      \"method\": \"CXCR1-specific blocking antibody and repertaxin treatment of breast cancer cell lines; ALDH/flow cytometry for CSC quantification; FASL/FAS apoptosis assays; FAK/AKT/FOXO3A pathway analysis; NOD/SCID xenograft models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell lines, two blocking agents, in vitro pathway analysis, and in vivo xenograft validation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"20051626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HIF-1 and NF-κB bind to the CXCR1 promoter and transcriptionally upregulate CXCR1 expression in response to hypoxia in prostate cancer cells; siRNA knockdown of HIF-1 or NF-κB, a HIF-1 dominant-negative, and pharmacological inhibitors all abrogate hypoxia-induced CXCR1 transcription.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) demonstrating HIF-1 and NF-κB binding to CXCR1; siRNA knockdown; HIF-1 dominant-negative construct; pharmacological inhibitors; RT-PCR and immunoblotting in PC3 prostate cancer cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP directly demonstrates transcription factor binding to CXCR1 locus; multiple independent approaches (siRNA, dominant-negative, pharmacological) confirm mechanism; single lab\",\n      \"pmids\": [\"17533374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mouse CXCR1 (mCXCR1) is a functional receptor predominantly engaged by mouse GCP-2/CXCL6 and human IL-8/CXCL8 (but not by CXCR2-selective ligands ENA-78, NAP-2, GRO-α/β/γ, or CINC-1-3), as demonstrated by ligand binding, GTPγS exchange stimulation, and chemotaxis of mCXCR1-transfected cells.\",\n      \"method\": \"Cloning of mCXCR1 cDNA; radioligand binding assays; [35S]-GTPγS exchange assay; chemotaxis of mCXCR1-transfected cells; ligand panel screening\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — three independent functional assays (binding, GTPγS, chemotaxis) with a defined ligand panel; single lab but rigorous biochemical characterization\",\n      \"pmids\": [\"17197447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Phagocytosis-induced downregulation of CXCR1 (and CXCR2) on human neutrophils occurs via metalloproteinase-dependent proteolytic degradation at the cell surface (not via internalization), as the metalloproteinase inhibitor 1,10-phenanthroline prevents reduction and confocal microscopy shows no internalization.\",\n      \"method\": \"Flow cytometry of CXCR1/CXCR2 surface expression after phagocytosis of opsonized yeast; metalloproteinase inhibitor treatment; confocal microscopy; Ca2+ response assays; RT-PCR for mRNA levels\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inhibitor pharmacology combined with confocal microscopy and mRNA analysis to distinguish proteolysis from internalization; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"12239185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CXCR1 internalization and recycling require actin-related kinase activity (sensitive to wortmannin); when both CXCR1 and CXCR2 are co-expressed, CXCR1 internalization is decreased compared to cells expressing only CXCR1, indicating receptor crosstalk during internalization.\",\n      \"method\": \"HEK293 transfectants with wild-type and chimeric/mutant CXCR1/CXCR2 constructs; wortmannin treatment; internalization and recycling assays; actin organization analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-mapping and pharmacological inhibition with multiple receptor constructs; single lab\",\n      \"pmids\": [\"12442335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCL8-induced chemotaxis via CXCR1 and CXCR2 is mediated through a pathway involving PI3K-dependent Cbl phosphorylation and Akt activation; Cbl overexpression (wild-type and G306E mutant, but not the RING-finger 70Z mutant) inhibits chemotaxis; kinase-dead Akt decreases both CXCL8-induced chemotaxis and Cbl phosphorylation; proteasome inhibitors block CXCR1/CXCR2 internalization.\",\n      \"method\": \"Cbl and Akt overexpression/dominant-negative in CXCR1/CXCR2-expressing L1.2 cells and human neutrophils; PI3K inhibitor LY294002; tyrphostin A9; proteasome inhibitors; co-immunoprecipitation of p85/Cbl; internalization assays\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple overexpression constructs and inhibitors, co-IP for Cbl-p85 interaction, single lab\",\n      \"pmids\": [\"16798838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCR1 interacts specifically with accessory proteins REEP5 and REEP6 (CXCR2 does not); REEP5/6 are required for ligand-stimulated CXCR1 endocytosis and β-arrestin2 intracellular clustering but not for baseline CXCR1 membrane expression; REEP5/6 depletion impairs IL-8-stimulated ERK phosphorylation and actin polymerization downstream of CXCR1.\",\n      \"method\": \"Co-immunoprecipitation of CXCR1 with REEP5/6; overexpression and siRNA knockdown of REEP5/6; receptor internalization assays; β-arrestin2 clustering by immunofluorescence; ERK phosphorylation and actin polymerization assays; A549 xenograft model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus gain/loss-of-function for accessory protein interaction; single lab, multiple functional readouts\",\n      \"pmids\": [\"27966653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The high-affinity IL-8 receptor gene (CXCR1/IL8RA) maps to chromosomal region 2q33-q36 and contains an intron in the 5' untranslated region; a pseudogene for the low-affinity IL-8 receptor (IL8RBP) was identified at a nearby locus.\",\n      \"method\": \"PCR-based cloning from genomic DNA; Southern blotting; in situ hybridization mapping to chromosome 2q33-q36; cDNA-genomic sequence comparison\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic mapping by in situ hybridization with sequence validation; foundational cloning study\",\n      \"pmids\": [\"8486366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In zebrafish, cxcl8/cxcr1 signaling (expressed in endothelial cells) positively regulates HSPC colonization by increasing HSPC-endothelial 'cuddling', HSPC residency time, and mitotic rate in the caudal hematopoietic tissue; enhanced cxcr1 signaling increases CHT volume and induces cxcl12a expression; cxcr1 acts hematopoietic stem cell-nonautonomously to improve donor HSPC engraftment in parabiotic zebrafish.\",\n      \"method\": \"Single-cell tracking of fluorescent HSPCs in zebrafish CHT; cxcr1 gain/loss-of-function; parabiotic zebrafish engraftment assay; cxcl12a expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live single-cell imaging, genetic manipulation, and parabiosis in zebrafish; ortholog study in vertebrate model, single lab\",\n      \"pmids\": [\"28351983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCR1 (but not CXCR2) deficiency in hepatocytes reduces exosome release and abolishes packaging of neutral ceramidase and sphingosine kinase into exosomes, eliminating the hepatocyte proliferative effect of these exosomes; CXCR2 deficiency increases exosome release through elevated neutral sphingomyelinase (Nsm) activity and ceramide production.\",\n      \"method\": \"CXCR1-/- and CXCR2-/- hepatocytes; exosome quantification; neutral sphingomyelinase activity assay; ceramide measurement; hepatocyte proliferation assay with conditioned exosomes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout hepatocytes with multiple biochemical and functional readouts; single lab\",\n      \"pmids\": [\"27551720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Natural posttranslational modifications of CXCL8 (N-terminal truncation to CXCL8(6-77) and citrullination to [Cit5]CXCL8) moderately enhance CXCR1 internalization and Gαi-dependent signaling, and increase β-arrestin 1 and 2 recruitment to CXCR1, without shifting the Gαi vs. β-arrestin signaling bias.\",\n      \"method\": \"Chemically synthesized CXCL8 variants; internalization assays with human neutrophils; Gαi-dependent signaling (HTRF); β-arrestin 1 and 2 recruitment assays to CXCR1 and CXCR2\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — chemically defined ligand variants tested across multiple receptor assay platforms; single lab\",\n      \"pmids\": [\"30486423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HIV-1 matrix protein p17 binds CXCR1 (and CXCR2) on endothelial cells with high affinity and promotes capillary-like structure formation via ERK/Akt signaling; p17 is internalized into endothelial cell nuclei through receptor-mediated endocytosis.\",\n      \"method\": \"High-affinity binding assays of p17 to CXCR2 and CXCR1 on endothelial cells; tube formation assay with blocking antibodies; ERK/Akt signaling analysis; ex vivo and in vivo angiogenesis models; confocal microscopy of p17 nuclear localization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding assays, functional tube formation with receptor blocking, signaling pathway analysis, in vivo models; single lab, multiple methods\",\n      \"pmids\": [\"22904195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CMV UL146-encoded vCXCL1 acts as a selective agonist of both CXCR1 and CXCR2 (affinities 44 nM and 5.6 nM respectively), activating calcium mobilization, phosphatidylinositol turnover, and chemotaxis, while not activating or blocking any of 16 other human chemokine receptors.\",\n      \"method\": \"Competition radioligand binding against CXCR1 and CXCR2; calcium mobilization; inositol triphosphate assay; chemotaxis assay in CHO, 300.19, COS7, and L1.2 cells expressing CXCR1 or CXCR2; panel of 18 chemokine receptor transfectants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — comprehensive receptor selectivity screen with four orthogonal functional assays and quantitative binding affinities; single lab, rigorous pharmacological characterization\",\n      \"pmids\": [\"20044480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCR1 drives dendritic cell-dependent inflammation through a positive feedback loop involving CXCL5/CXCR1/HIF-1α signaling that directly regulates IL-6 and IL-12p70 production; DC-specific CXCR1 deletion suppresses inflammatory cytokine secretion and ameliorates EAE and LPS-induced ARDS.\",\n      \"method\": \"CXCR1 global and DC-specific knockout mice; EAE and ARDS models; antibody neutralization of CXCL5; cytokine ELISA; HIF-1α pathway analysis in DCs\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific knockout combined with two disease models and molecular pathway identification; single lab\",\n      \"pmids\": [\"37709757\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCR1 is a G protein-coupled, seven-transmembrane chemokine receptor that binds IL-8/CXCL8 (and selectively GCP-2/CXCL6) through a two-site mechanism involving its membrane-constrained N-terminal domain (site I) and juxtamembrane domain (site II); upon ligand binding it activates Gi-independent Rho/Rho-kinase signaling leading to actin stress fiber formation, and triggers GRK2/β-arrestin/dynamin-dependent clathrin-mediated internalization that is regulated by C-terminal phosphorylation sites, with CXCR1 and CXCR2 constitutively forming homo- and heterodimers and showing distinct internalization kinetics governed by their respective second extracellular loops; CXCR1 uniquely activates PKCε (mediating exocytosis/degranulation and cross-desensitization of CCR5) and its expression is transcriptionally driven by HIF-1 and NF-κB under hypoxia; functionally, CXCR1-dependent neutrophil degranulation is essential for antifungal and anti-Pseudomonas host defense, and CXCR1 governs dendritic cell IL-6/IL-12 production via a CXCL5/HIF-1α feedback loop, while also regulating hepatocyte exosome composition and hematopoietic stem cell niche remodeling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CXCR1 is a seven-transmembrane, G protein-coupled chemokine receptor that binds IL-8/CXCL8 and selectively the mouse ligand GCP-2/CXCL6 to drive neutrophil and leukocyte effector functions in innate host defense [#15]. Ligand recognition follows a membrane-constrained two-site logic: the isolated N-terminal domain binds IL-8 with micromolar affinity and adopts a structured, membrane-interacting conformation only in a micelle/bilayer environment, a conformational constraint that governs ligand selectivity at site I [#3], while the assembled receptor undergoes rapid rotational diffusion in the bilayer with mobile termini and dynamically restricted transmembrane helices [#9]. Beyond canonical Gi coupling, CXCR1 activates a Gi-independent Rho/Rho-kinase cascade that builds actin stress fibers [#0] and uniquely engages PKCε to mediate receptor exocytosis and cross-desensitization of CCR5 [#5]. Agonist binding triggers GRK2/β-arrestin/dynamin-dependent clathrin-mediated internalization controlled by a C-terminal cluster of phosphorylation sites, with subsequent recycling to the surface [#1, #2]; CXCL8 monomer is the more potent driver of phosphorylation, β-arrestin recruitment and internalization than the dimer [#7]. CXCR1 constitutively forms homo- and heterodimers with CXCR2 assembled during biosynthesis [#4], and distinct second-extracellular-loop determinants set its slower internalization kinetics relative to CXCR2 [#6]. Functionally, CXCR1 is required cell-intrinsically for neutrophil degranulation and microbial killing in candidiasis and anti-Pseudomonas pulmonary defense, independent of trafficking, with a human CXCR1-T276 variant impairing this effector arm [#11, #12]. Its expression is transcriptionally induced under hypoxia by HIF-1 and NF-κB binding to the CXCR1 promoter [#14], and CXCR1 signaling extends to dendritic cell cytokine production via a CXCL5/HIF-1α feedback loop [#26] and to breast cancer stem cell survival, where blockade triggers FAS/FASL apoptosis through the FAK/AKT/FOXO3A pathway [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing the genomic identity and locus of the high-affinity IL-8 receptor was the foundational step that defined CXCR1 as a discrete gene distinct from its low-affinity counterpart.\",\n      \"evidence\": \"PCR cloning, Southern blotting and in situ hybridization mapping to chromosome 2q33-q36\",\n      \"pmids\": [\"8486366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not address receptor function or ligand specificity\", \"No protein-level characterization\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The internalization machinery and the C-terminal determinant controlling it were defined, distinguishing CXCR1 desensitization from CXCR2.\",\n      \"evidence\": \"Dominant-negative GRK2/β-arrestin1/dynamin constructs with CXCR1-GFP and C-terminal deletion mutants in HEK293/RBL-2H3 cells\",\n      \"pmids\": [\"10347185\", \"10623425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylated residues among the six sites not individually mapped\", \"Kinetics in primary neutrophils not assessed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"CXCR1 was shown to drive a Gi-independent Rho/Rho-kinase signaling arm, separating its cytoskeletal output from CXCR2's Gi/Rac-mediated response.\",\n      \"evidence\": \"Dominant-negative Rho/Rac, C3 toxin, Y-27632, pertussis toxin and receptor-blocking antibodies in microvascular endothelial cells\",\n      \"pmids\": [\"11350788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream link between receptor and Rho activation not defined\", \"Endothelial-specific vs leukocyte signaling not compared\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"NMR demonstrated that membrane environment constrains the N-domain conformation, providing the structural basis for site-I ligand selectivity.\",\n      \"evidence\": \"Solution and detergent-micelle NMR of the isolated CXCR1 N-domain with IL-8 and MGSA binding measurements\",\n      \"pmids\": [\"15133028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isolated peptide, not full-length receptor in native membrane\", \"Site-II contribution not addressed here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"CXCR1 was found to constitutively dimerize with itself and CXCR2 during biosynthesis, and to uniquely couple to PKCε for exocytosis and CCR5 cross-desensitization.\",\n      \"evidence\": \"BRET/FRET/co-IP with ER trapping in HEK293; PKCε inhibitor peptide, PKCε-/- macrophages and CXCR1/CXCR2 chimeras\",\n      \"pmids\": [\"15946947\", \"15905535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of heterodimerization on signaling output not fully resolved\", \"PKCε activation mechanism downstream of receptor unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Cloning of mouse CXCR1 established its ligand specificity (GCP-2/CXCL6 and human IL-8) and validated a tractable ortholog for in vivo study.\",\n      \"evidence\": \"Radioligand binding, GTPγS exchange and chemotaxis of mCXCR1 transfectants against a ligand panel\",\n      \"pmids\": [\"17197447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous mouse ligand in vivo not defined\", \"Receptor signaling differences between species not characterized\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The second extracellular loop, and specifically Asp199 in CXCR2, was identified as the structural switch governing the divergent internalization kinetics of the two receptors.\",\n      \"evidence\": \"CXCR1/CXCR2 domain swaps and D199V/D199N point mutants with comprehensive functional assays in RBL-2H3 cells\",\n      \"pmids\": [\"17204468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How 2ECL identity is transmitted to the endocytic machinery is unresolved\", \"Physiological relevance of kinetic difference not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Hypoxic transcriptional control of CXCR1 was established by direct HIF-1 and NF-κB binding to its promoter.\",\n      \"evidence\": \"ChIP, siRNA, HIF-1 dominant-negative and pharmacological inhibitors in PC3 prostate cancer cells\",\n      \"pmids\": [\"17533374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter element coordinates not detailed\", \"Relevance to neutrophil/immune cell expression not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Ligand oligomeric state was shown to bias CXCR1 responses, with the CXCL8 monomer driving more rapid phosphorylation, β-arrestin translocation and internalization than the dimer.\",\n      \"evidence\": \"Trapped CXCL8 monomer (L25NMe) and dimer (R26C) across neutrophils and CXCR1/CXCR2 RBL cells with multiple functional readouts; dynamic FRET dimer analysis\",\n      \"pmids\": [\"19667085\", \"19890050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for monomer preference at CXCR1 not defined\", \"Quantitative dimer/monomer balance in vivo unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Solid-state and solution NMR of full-length CXCR1 in bilayers defined its rotational dynamics and the restricted mobility of transmembrane helices in a native-like environment.\",\n      \"evidence\": \"Solution NMR in bicelles and solid-state NMR of aligned bilayers with full-length and truncated constructs\",\n      \"pmids\": [\"21323370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution atomic structure of the receptor\", \"Ligand-bound dynamics not captured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genetic dissection in mice and a human variant showed CXCR1's host-defense role lies in cell-intrinsic neutrophil degranulation and microbial killing, not trafficking.\",\n      \"evidence\": \"Cxcr1-/- mouse candidiasis and Pseudomonas airway models, ROS/TLR5 analysis, and CXCR1-T276 patient neutrophil function\",\n      \"pmids\": [\"26791948\", \"26950764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link from CXCR1 to degranulation/ROS not fully mapped\", \"Mechanism of TLR5 modulation unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Accessory proteins REEP5/6 were identified as CXCR1-selective partners required for ligand-stimulated endocytosis and downstream signaling.\",\n      \"evidence\": \"Co-IP, overexpression and siRNA of REEP5/6 with internalization, β-arrestin2 clustering, ERK and actin assays; A549 xenograft\",\n      \"pmids\": [\"27966653\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of CXCR1-REEP interaction unknown\", \"Single-lab co-IP without reciprocal in vivo validation\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CXCR1 was shown to control hepatocyte exosome biogenesis and cargo packaging, extending its role beyond chemotaxis to vesicle-mediated intercellular signaling.\",\n      \"evidence\": \"CXCR1-/- and CXCR2-/- hepatocytes with exosome quantification, sphingomyelinase/ceramide assays and proliferation readouts\",\n      \"pmids\": [\"27551720\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway from receptor to exosome machinery undefined\", \"Ligand driving this hepatocyte function unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"CXCR1 blockade was shown to selectively kill breast cancer stem cells, defining a non-immune oncogenic function via FAS/FASL and FAK/AKT/FOXO3A signaling.\",\n      \"evidence\": \"Repertaxin and blocking antibody in breast cancer cell lines, ALDH/flow CSC quantification, pathway analysis and NOD/SCID xenografts\",\n      \"pmids\": [\"20051626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligand sustaining CSC survival not identified\", \"Direct receptor-to-FAK coupling mechanism unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Pathogen-derived and pharmacological ligands clarified CXCR1's druggable allosteric pocket and its exploitation by viral mimics.\",\n      \"evidence\": \"DF2156A allosteric inhibitor binding via Lys99 (radioligand/GTPγS/chemotaxis with modeling) and HIV-1 p17 high-affinity binding driving angiogenesis via ERK/Akt\",\n      \"pmids\": [\"21718305\", \"22904195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Allosteric mechanism not validated structurally\", \"Physiological consequence of p17 engagement in HIV infection unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Posttranslationally modified CXCL8 forms were shown to modulate CXCR1 internalization and signaling magnitude without altering the Gαi/β-arrestin bias.\",\n      \"evidence\": \"Synthetic CXCL8(6-77) and [Cit5]CXCL8 variants in neutrophil internalization, HTRF Gαi and β-arrestin recruitment assays\",\n      \"pmids\": [\"30486423\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo abundance and relevance of modified ligands unknown\", \"Structural basis of altered potency undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"DC-specific deletion established a CXCL5/CXCR1/HIF-1α feedback loop controlling IL-6 and IL-12 production and inflammatory disease severity.\",\n      \"evidence\": \"Global and DC-specific CXCR1 knockout mice in EAE and ARDS models with CXCL5 neutralization and HIF-1α pathway analysis\",\n      \"pmids\": [\"37709757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CXCR1-HIF-1α coupling mechanism in DCs not resolved\", \"Whether feedback operates in human DCs untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CXCR1's distinct downstream effectors (Rho/Rho-kinase, PKCε, REEP5/6, exosome machinery) are selectively engaged by a single receptor, and what governs ligand-, dimer-, and tissue-specific output, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution ligand-bound structure to rationalize biased signaling\", \"Mechanistic link from receptor to tissue-specific effector programs (degranulation, exosomes, CSC survival) not unified\", \"Endogenous human ligand specificity in each context incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 15, 25]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 15]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [24, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 9]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [1, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 12, 26]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1, 2, 19]}\n    ],\n    \"complexes\": [\"CXCR1-CXCR2 homo/heterodimer\"],\n    \"partners\": [\"CXCR2\", \"GRK2\", \"ARRB1\", \"DNM1\", \"PRKCE\", \"REEP5\", \"REEP6\", \"CBL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}